A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC)

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC)

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Astrocytoma; Tuberous sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EXIST-1
  • Sponsors Novartis
  • Most Recent Events

    • 21 Apr 2016 Results (n=119) of pooled analysis of 3 studies (NCT00411619, NCT00789828 and NCT00790400) analysing endocrine and menstrual cycle-related events in females presented at the 68th Annual Meeting of the American Academy of Neurology
    • 08 Mar 2016 Long-term results from this trial and from EXIST-2 trial presented at the 74th Annual Meeting of the American Academy of Dermatology
    • 05 Feb 2016 Results of post-hoc subgroup analysis published in the Journal of Pediatrics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top